Kairos Pharma, Ltd.
$0.63
▲
0.4%
2026-04-21 07:41:01
kairospharma.com
ASE: KAPA
Explore Kairos Pharma, Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.1 M
Current Price
$0.63
52W High / Low
$2.11 / $0.4
Stock P/E
—
Book Value
$0.37
Dividend Yield
—
ROCE
-87.87%
ROE
-97.99%
Face Value
—
EPS
$-0.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
1
Beta
—
Debt / Equity
—
Current Ratio
27.07
Quick Ratio
27.07
Forward P/E
-1.07
Price / Sales
—
Enterprise Value
$8 M
EV / EBITDA
-1.48
EV / Revenue
—
Rating
Strong Buy
Target Price
$8.33
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
| 2. | Elicio Therapeutics, Inc. | $12.2 | — | $224.43 M | — | -210.11% | 817.92% | $14.93 / $4.7 | $0.09 |
| 3. | Anixa Biosciences, Inc. | $3 | — | $100.58 M | — | -82.91% | -68.06% | $5.46 / $2.44 | $0.45 |
| 4. | Vaxcyte, Inc. | $61.4 | — | $8.86 B | — | -33.02% | -25.59% | $65 / $28.09 | $20.49 |
| 5. | Adaptive Biotechnologies Corporation | $14.58 | — | $2.23 B | — | -13.51% | -27.82% | $20.76 / $6.77 | $1.42 |
| 6. | Iovance Biotherapeutics, Inc. | $3.78 | — | $1.56 B | — | -51.39% | -55.5% | $5.63 / $1.64 | $1.7 |
| 7. | Moolec Science SA | $7.28 | — | $5.29 M | — | 11.2% | 344.24% | $157.05 / $3.07 | $0.7 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -1.42 M | -1.44 M | -1.46 M | -1.27 M | -1.45 M | — |
| Net Profit | -1.36 M | -1.4 M | -1.42 M | -1.26 M | -0.98 M | — |
| EPS in Rs | -0.06 | -0.07 | -0.07 | -0.06 | -0.05 | -0.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -5.57 M | -2.34 M | -1.71 M | -0.57 M |
| Net Profit | -5.45 M | -2.6 M | -1.81 M | -1.05 M |
| EPS in Rs | -0.25 | -0.12 | -0.08 | -0.05 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 6.54 M | 5.77 M | 0.96 M | 1.04 M |
| Total Liabilities | 0.2 M | 0.99 M | 3.04 M | 2.21 M |
| Equity | 6.34 M | 4.78 M | -2.08 M | -1.18 M |
| Current Assets | 5.39 M | 4.17 M | 0.1 M | 0.44 M |
| Current Liabilities | 0.2 M | 0.99 M | 2.4 M | 1.63 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -3.44 M | -3.96 M | 0.08 M | -0.35 M |
| Investing CF | — | — | — | 0 M |
| Financing CF | 6.66 M | 5.13 M | -0.42 M | 0.72 M |
| Free CF | -3.44 M | -3.96 M | 0.08 M | -0.35 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -43.65% | -72.57% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.